does semaglutide lose effectiveness Choosing Oral vs. Injectable for Weight Loss The Pros and Cons of
Description
No insurance needed and no membership fees
GLP-1 receptor agonists, already used for Type 2 diabetes and obesity, show promise in reducing alcohol and drug-seeking behaviors through central reward and dopamine-related pathways

Zooming out, the obesity market is now clearly split across modalities: Novo Nordisk still anchors the peptide side with semaglutide, while oral small molecules are accelerating (orforglipron, elecoglipron and Roches Carmot deal)

Bad breath can develop during GLP-1 therapy, but it's usually manageable with simple oral hygiene adjustments

Nobody starts a GLP-1 journey hoping to become smaller and weaker

p=0.001), HbA1c levels (1.48 [1.75, 1.21]
